STOCK TITAN

[Form 4] Guardant Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Tariq Musa of Guardant Health reported multiple transactions on June 18, 2025:

  • Sale: Disposed of 3,213 shares of common stock at $49.47 per share, retaining 7,190 shares after the transaction
  • Stock Options: Received 6,833 stock options with exercise price of $50.57, expiring June 18, 2035
  • RSUs: Granted 4,203 restricted stock units

Both the stock options and RSUs vest in full on the earlier of June 18, 2026, or the date of the next annual stockholders meeting. This filing represents standard equity compensation for a board member, with a simultaneous sale of existing shares. The transaction was executed through an attorney-in-fact, John G. Saia.

Il direttore Tariq Musa di Guardant Health ha riportato diverse operazioni il 18 giugno 2025:

  • Vendita: Ha ceduto 3.213 azioni ordinarie a 49,47 dollari per azione, mantenendo 7.190 azioni dopo la transazione
  • Opzioni su azioni: Ha ricevuto 6.833 opzioni con prezzo di esercizio di 50,57 dollari, con scadenza il 18 giugno 2035
  • RSU: Gli sono state assegnate 4.203 unità azionarie vincolate

Sia le opzioni su azioni che le RSU maturano completamente alla data anticipata tra il 18 giugno 2026 o la data della prossima assemblea annuale degli azionisti. Questa comunicazione rappresenta una normale compensazione azionaria per un membro del consiglio, con una vendita simultanea di azioni esistenti. L’operazione è stata eseguita tramite un procuratore, John G. Saia.

El director Tariq Musa de Guardant Health informó varias transacciones el 18 de junio de 2025:

  • Venta: Disposición de 3,213 acciones ordinarias a 49.47 dólares por acción, conservando 7,190 acciones después de la operación
  • Opciones sobre acciones: Recibió 6,833 opciones con precio de ejercicio de 50.57 dólares, que expiran el 18 de junio de 2035
  • RSU: Se le otorgaron 4,203 unidades restringidas de acciones

Tanto las opciones sobre acciones como las RSU se consolidan completamente en la fecha que ocurra primero entre el 18 de junio de 2026 o la próxima junta anual de accionistas. Esta presentación representa una compensación accionaria estándar para un miembro del consejo, junto con una venta simultánea de acciones existentes. La transacción fue ejecutada a través de un apoderado legal, John G. Saia.

Guardant Health의 이사 Tariq Musa는 2025년 6월 18일 여러 거래를 보고했습니다:

  • 매도: 보통주 3,213주를 주당 49.47달러에 처분하였으며, 거래 후 7,190주를 보유
  • 주식 옵션: 행사 가격 50.57달러, 만기일 2035년 6월 18일인 주식 옵션 6,833주를 수령
  • 제한 주식 단위(RSU): 4,203개의 제한 주식 단위 부여

주식 옵션과 RSU는 2026년 6월 18일 또는 다음 연례 주주총회 중 빠른 시점에 전액 취득됩니다. 이 보고는 이사회 구성원에 대한 표준 주식 보상이며, 기존 주식의 동시 매도도 포함됩니다. 거래는 법정 대리인 John G. Saia를 통해 실행되었습니다.

Le directeur Tariq Musa de Guardant Health a déclaré plusieurs transactions le 18 juin 2025 :

  • Vente : Cession de 3 213 actions ordinaires à 49,47 $ par action, conservant 7 190 actions après la transaction
  • Options d’achat d’actions : Réception de 6 833 options d’achat avec un prix d’exercice de 50,57 $, expirant le 18 juin 2035
  • RSU : Attribution de 4 203 unités d’actions restreintes

Les options d’achat et les RSU deviennent entièrement acquises à la date la plus proche entre le 18 juin 2026 ou la prochaine assemblée générale annuelle des actionnaires. Cette déclaration correspond à une rémunération en actions standard pour un membre du conseil d’administration, accompagnée d’une vente simultanée d’actions existantes. La transaction a été réalisée par un mandataire, John G. Saia.

Direktor Tariq Musa von Guardant Health meldete am 18. Juni 2025 mehrere Transaktionen:

  • Verkauf: Verkauf von 3.213 Stammaktien zu je 49,47 USD, nach der Transaktion verbleiben 7.190 Aktien
  • Aktienoptionen: Erhielt 6.833 Aktienoptionen mit einem Ausübungspreis von 50,57 USD, Ablaufdatum 18. Juni 2035
  • RSUs: Gewährt wurden 4.203 Restricted Stock Units

Sowohl die Aktienoptionen als auch die RSUs werden vollständig fällig am jeweils früheren Datum von 18. Juni 2026 oder der nächsten jährlichen Hauptversammlung. Diese Meldung stellt eine übliche Aktienvergütung für ein Vorstandsmitglied dar, verbunden mit einem gleichzeitigen Verkauf bestehender Aktien. Die Transaktion wurde durch einen Bevollmächtigten, John G. Saia, ausgeführt.

Positive
  • Director received new equity compensation with 6,833 stock options at $50.57 strike price and 4,203 RSUs, aligning long-term interests with shareholders
Negative
  • Director Tariq Musa sold 3,213 shares at $49.47, reducing direct holdings to 7,190 shares

Il direttore Tariq Musa di Guardant Health ha riportato diverse operazioni il 18 giugno 2025:

  • Vendita: Ha ceduto 3.213 azioni ordinarie a 49,47 dollari per azione, mantenendo 7.190 azioni dopo la transazione
  • Opzioni su azioni: Ha ricevuto 6.833 opzioni con prezzo di esercizio di 50,57 dollari, con scadenza il 18 giugno 2035
  • RSU: Gli sono state assegnate 4.203 unità azionarie vincolate

Sia le opzioni su azioni che le RSU maturano completamente alla data anticipata tra il 18 giugno 2026 o la data della prossima assemblea annuale degli azionisti. Questa comunicazione rappresenta una normale compensazione azionaria per un membro del consiglio, con una vendita simultanea di azioni esistenti. L’operazione è stata eseguita tramite un procuratore, John G. Saia.

El director Tariq Musa de Guardant Health informó varias transacciones el 18 de junio de 2025:

  • Venta: Disposición de 3,213 acciones ordinarias a 49.47 dólares por acción, conservando 7,190 acciones después de la operación
  • Opciones sobre acciones: Recibió 6,833 opciones con precio de ejercicio de 50.57 dólares, que expiran el 18 de junio de 2035
  • RSU: Se le otorgaron 4,203 unidades restringidas de acciones

Tanto las opciones sobre acciones como las RSU se consolidan completamente en la fecha que ocurra primero entre el 18 de junio de 2026 o la próxima junta anual de accionistas. Esta presentación representa una compensación accionaria estándar para un miembro del consejo, junto con una venta simultánea de acciones existentes. La transacción fue ejecutada a través de un apoderado legal, John G. Saia.

Guardant Health의 이사 Tariq Musa는 2025년 6월 18일 여러 거래를 보고했습니다:

  • 매도: 보통주 3,213주를 주당 49.47달러에 처분하였으며, 거래 후 7,190주를 보유
  • 주식 옵션: 행사 가격 50.57달러, 만기일 2035년 6월 18일인 주식 옵션 6,833주를 수령
  • 제한 주식 단위(RSU): 4,203개의 제한 주식 단위 부여

주식 옵션과 RSU는 2026년 6월 18일 또는 다음 연례 주주총회 중 빠른 시점에 전액 취득됩니다. 이 보고는 이사회 구성원에 대한 표준 주식 보상이며, 기존 주식의 동시 매도도 포함됩니다. 거래는 법정 대리인 John G. Saia를 통해 실행되었습니다.

Le directeur Tariq Musa de Guardant Health a déclaré plusieurs transactions le 18 juin 2025 :

  • Vente : Cession de 3 213 actions ordinaires à 49,47 $ par action, conservant 7 190 actions après la transaction
  • Options d’achat d’actions : Réception de 6 833 options d’achat avec un prix d’exercice de 50,57 $, expirant le 18 juin 2035
  • RSU : Attribution de 4 203 unités d’actions restreintes

Les options d’achat et les RSU deviennent entièrement acquises à la date la plus proche entre le 18 juin 2026 ou la prochaine assemblée générale annuelle des actionnaires. Cette déclaration correspond à une rémunération en actions standard pour un membre du conseil d’administration, accompagnée d’une vente simultanée d’actions existantes. La transaction a été réalisée par un mandataire, John G. Saia.

Direktor Tariq Musa von Guardant Health meldete am 18. Juni 2025 mehrere Transaktionen:

  • Verkauf: Verkauf von 3.213 Stammaktien zu je 49,47 USD, nach der Transaktion verbleiben 7.190 Aktien
  • Aktienoptionen: Erhielt 6.833 Aktienoptionen mit einem Ausübungspreis von 50,57 USD, Ablaufdatum 18. Juni 2035
  • RSUs: Gewährt wurden 4.203 Restricted Stock Units

Sowohl die Aktienoptionen als auch die RSUs werden vollständig fällig am jeweils früheren Datum von 18. Juni 2026 oder der nächsten jährlichen Hauptversammlung. Diese Meldung stellt eine übliche Aktienvergütung für ein Vorstandsmitglied dar, verbunden mit einem gleichzeitigen Verkauf bestehender Aktien. Die Transaktion wurde durch einen Bevollmächtigten, John G. Saia, ausgeführt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tariq Musa

(Last) (First) (Middle)
3100 HANOVER STREET

(Street)
PALO ALTO CA 94304

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 S 3,213 D $49.47 7,190 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $50.57 06/18/2025 A 6,833 (1) 06/18/2035 Common Stock 6,833 $0 6,833 D
Restricted Stock Units $0 06/18/2025 A 4,203 (2) (3) Common Stock 4,203 $0 4,203 D
Explanation of Responses:
1. The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
2. The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier.
3. Not applicable for Restricted Stock Units.
Remarks:
/s/ John G. Saia, as attorney-in-fact for Musa Tariq 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trading activity occurred at Guardant Health (GH) on June 18, 2025?

On June 18, 2025, Director Tariq Musa sold 3,213 shares of GH common stock at $49.47 per share. Additionally, Musa was granted 6,833 stock options with an exercise price of $50.57 and 4,203 Restricted Stock Units (RSUs).

How many shares does Tariq Musa own after the recent GH stock transaction?

Following the reported transactions, Tariq Musa directly owns 7,190 shares of Guardant Health (GH) common stock, 6,833 stock options, and 4,203 Restricted Stock Units.

What are the vesting terms for GH's new stock options granted to Tariq Musa?

The stock options granted on June 18, 2025, will vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next year annual stockholders meeting, whichever occurs earlier. The options have an expiration date of June 18, 2035.

When do Tariq Musa's new Guardant Health (GH) RSUs vest?

The 4,203 Restricted Stock Units (RSUs) granted on June 18, 2025, will vest in full on the one-year anniversary of the grant date (June 18, 2025) or the date of the next year annual stockholders meeting, whichever occurs earlier.
Guardant Health

NASDAQ:GH

GH Rankings

GH Latest News

GH Latest SEC Filings

GH Stock Data

6.01B
118.13M
4.71%
98.48%
6.4%
Diagnostics & Research
Services-medical Laboratories
Link
United States
PALO ALTO